Deprecated: Creation of dynamic property Penci_AMP_Post_Template::$ID is deprecated in /home/u444474283/domains/gwcmag.com/public_html/wp-content/plugins/penci-soledad-amp/includes/class-amp-post-template.php on line 46

Deprecated: Creation of dynamic property Penci_AMP_Post_Template::$post is deprecated in /home/u444474283/domains/gwcmag.com/public_html/wp-content/plugins/penci-soledad-amp/includes/class-amp-post-template.php on line 47
Novo Nordisk Says Experimental Drug Amycretin Show 13% Weight Loss In Trial  - GWC Mag - Your Trusted Source For Green Technology, Sustainability, And Environmental Innovation Novo Nordisk Says Experimental Drug Amycretin Show 13% Weight Loss In Trial  - GWC Mag - Your Trusted Source For Green Technology, Sustainability, And Environmental Innovation
Green Health & Wellness

Novo Nordisk says experimental drug amycretin show 13% weight loss in trial  – GWC Mag

gwcmag035 views

Business & FinanceHealth

07 March 2024, 2:04 pm 1 minute

Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. 

Market Impact

Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously.

Article Tags

Topics of Interest: Business & FinanceHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Related posts

Gossiping can benefit mental health, but also presents risks, experts say – GWC Mag

Johnson & Johnson (JNJ) earnings Q1 2024 – GWC Mag

UnitedHealth says Change Healthcare cyberattack cost it $872 million – GWC Mag

Add Comment